Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

  • Awaiting development
  • GID-TA11383
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Dupilumab within its marketing authorisation for treating oesophagitis in paediatric patients